Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
Wasatch Advisors LP filed Amendment No. 1 to Schedule 13G for Inspire Medical Systems (INSP), reporting beneficial ownership of 135,914 common shares, representing 0.5% of the class as of September 30, 2025.
The firm holds sole voting and sole dispositive power over all reported shares. It certified the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Inspire Medical Systems reported Q3 2025 growth with lower profitability. Revenue rose to $224.5 million from $203.2 million as U.S. sales remained the core driver. Gross profit reached $192.7 million, but higher operating costs, including advertising and SG&A, reduced operating income to $9.6 million from $14.3 million.
Net income was $9.9 million versus $18.5 million a year ago, with diluted EPS of $0.34 versus $0.60. For the first nine months, revenue was $642.9 million and net income was $9.3 million. Cash and cash equivalents were $112.8 million, with $209.7 million in short-term investments. Inventories increased to $141.8 million from $80.1 million, reflecting production and demand planning.
The company continued capital returns: it completed an accelerated share repurchase totaling 409,043 shares at an average price of $190.29, repurchased 442,649 shares for $75.0 million earlier in 2025, and bought 552,423 shares for $50.0 million under a new $200.0 million program, leaving $150.0 million authorized. Shares outstanding were 29,053,367 at September 30, 2025.
Inspire Medical Systems reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished an investor presentation for upcoming meetings with investors and analysts.
The materials are provided as Exhibits 99.1 (press release) and 99.2 (presentation). The company noted these items are furnished, not filed, under the Exchange Act. The investor presentation is also available on the company’s Investor Relations website.
BlackRock, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Inspire Medical Systems (INSP). As of September 30, 2025, BlackRock beneficially owned 3,353,407 shares of INSP, representing 11.3% of the common stock. The filing lists sole voting power over 3,283,122 shares and sole dispositive power over 3,353,407 shares, with no shared voting or dispositive power.
BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF has an interest in INSP common stock that is more than five percent of the total outstanding shares.
Inspire Medical Systems (INSP) reported an insider transaction by a director. On 10/14/2025, the director acquired 229 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this transaction, the director beneficially owns 3,986 shares, held directly.
Inspire Medical Systems (INSP) director Casey M. Tansey reported an equity award. On 10/14/2025, Tansey acquired 221 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.
Following this transaction, Tansey beneficially owned 22,235 shares directly. Additional indirect holdings reported include 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.
Inspire Medical Systems (INSP) director Gary L. Ellis reported acquiring 372 shares of common stock on October 14, 2025. The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reported price of $78.84 per share.
Following this transaction, Ellis beneficially owns 6,454 shares, held directly. This filing reflects routine director compensation settled in stock rather than cash.
Inspire Medical Systems (INSP) reported an insider equity award. Director Shelley G. Broader acquired 245 shares of common stock on 10/14/2025 at $78.84 per share. The shares were received in lieu of cash fees under the company's Non-Employee Director Compensation Policy.
After this transaction, Broader’s beneficial ownership stands at 4,367 shares, held directly.
Inspire Medical Systems, Inc. filed a current report describing upcoming investor and analyst meetings in October 2025. The company is using a prepared slide presentation for these meetings, which is furnished as Exhibit 99.2 and made available on its investor relations website.
The filing also lists a related press release as Exhibit 99.1. The company clarifies that the presentation materials and related disclosure are furnished, not filed, so they are not subject to certain Exchange Act liability provisions or automatically incorporated into other securities law filings.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G reporting ownership of common stock of Inspire Medical Systems, Inc. The filing shows an aggregate beneficial ownership of 741,312.10 shares, representing 2.5% of the outstanding common stock. FMR LLC reports sole voting power of 739,599 shares and sole dispositive power of 741,312.10 shares; Abigail P. Johnson reports sole dispositive power of 741,312.10 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing control. The filing includes referenced exhibits and powers of attorney.